>중동 및 아프리카 림프부종 치료 시장, 치료 유형(압박 요법, 수술, 약물 요법, 레이저 요법 및 기타), 유형(1차 림프부종 및 2차 림프부종), 영향을 받는 부위(생식기, 하지, 상지 및 기타), 연령대(성인 및 노인), 투여 경로(경구, 주사 및 기타), 최종 사용자(병원, 외래 수술 센터, 전문 병원 및 기타), 유통 채널(직접 입찰, 약국 매장 및 기타), 국가(남아프리카, 사우디 아라비아, UAE, 쿠웨이트, 이스라엘 및 중동 및 아프리카의 나머지 지역) 산업 동향 및 2029년까지의 예측
시장 분석 및 통찰력: 중동 및 아프리카 림프부종 치료 시장
중동 및 아프리카 림프부종 치료 시장은 2022년부터 2029년까지의 예측 기간 동안 상당한 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 중동 및 아프리카 림프부종 치료 시장이 2022년부터 2029년까지의 예측 기간 동안 5.3%의 CAGR로 성장하고 있으며 2022년 967만 달러에서 2029년까지 1,435만 달러에 도달할 것으로 예상한다고 분석합니다. 증가하는 의료비 지출과 혁신 및 기술의 확대는 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다.
림프부종은 일반적으로 상지와 하지에 발생하는 부기를 말합니다. 때로는 두 팔과 두 다리가 부기도 합니다. 림프부종은 암 치료의 일환으로 림프절을 제거하거나 손상시켜 가장 흔히 발생합니다. 면역 체계의 일부인 림프계가 막혀 발생합니다. 손상된 림프계에서 비롯되며 감염, 변형, 쇠약해지는 통증 및 장애로 이어질 수 있습니다. 림프부종을 치료할 수 있는 방법은 없습니다.
림프부종 치료는 표준 치료 대신 여러 가지 요법을 포함합니다. 환자들이 림프부종의 기존 치료에 불만족하거나 치료되지 않기 때문입니다. 그들은 건강 관리 결정에 대한 통제력을 더 많이 제공하는 대체 치료법에 접근하며, 대안은 환자의 건강 시스템과 더 호환되는 것으로 밝혀졌습니다.
림프부종은 림프절 배수에 영향을 미치는 암이나 치료 후에 발생할 수 있습니다. 유방암 치료 후 며칠에서 최대 30년 후에 발생하는 것으로 보고되었습니다. 초기 단계 림프부종 치료에는 요법, 수술 및 림프정맥 이식 등이 있습니다. 그러나 림프부종을 영구적으로 치료할 수 있는 방법은 없습니다.
점점 더 많은 사람들이 림프부종에 시달리고 있으며, 치료 중 위험을 최소화하기 위해 매우 효과적이고 진보된 치료가 필요합니다. 의료 시스템은 환자 치료 중 수많은 림프부종 장애에 대한 매우 진보된 치료법이 필요합니다. 따라서 주요 시장 참여자들은 제품 출시와 제품 승인에 매우 집중하고 있습니다. 또한 정부와 규제 기관은 제품 승인을 통해 시장 참여자들을 지원하고 있습니다.
지난 10년 동안 림프부종 환자 수가 증가함에 따라 전 세계적으로 림프부종 치료에 대한 수요가 급증했습니다.
높은 치료 비용과 치료와 관련된 부작용은 예상 기간 동안 시장 성장을 방해할 것으로 예상됩니다.
시장 참여자들의 전략적 이니셔티브, 의료비 지출 증가, 약물 제조업체 수의 급증은 이 시장에 기회로 작용하고 있으며 시장 성장을 촉진할 것으로 예상됩니다.
림프부종을 영구적으로 치료할 수 있는 방법이 없다는 점이 중동과 아프리카 림프부종 치료 시장의 미래 성장을 위한 가장 큰 과제가 될 것으로 예상됩니다.
중동 및 아프리카 림프부종 치료 시장 보고서는 시장 점유율, 새로운 개발 및 제품 파이프라인 분석, 국내 및 현지 시장 참여자의 영향, 새로운 수익 주머니, 시장 규정의 변화, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 시장의 기술 혁신 측면에서의 분석 기회에 대한 세부 정보를 제공합니다. 분석 및 시장 시나리오를 이해하려면 분석가 브리핑을 위해 당사에 문의하세요. 당사 팀은 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드립니다.
중동 및 아프리카 림프부종 치료 시장 및 시장 규모
중동 및 아프리카 림프부종 치료 시장은 치료 유형, 유형, 영향을 받는 지역, 연령대, 투여 경로, 최종 사용자, 유통 채널에 따라 세분화됩니다. 세그먼트 간의 성장은 틈새 성장 포켓과 시장에 접근하고 핵심 응용 분야와 타겟 시장의 차이점을 파악하기 위한 전략을 분석하는 데 도움이 됩니다.
- 치료 유형을 기준으로 중동 및 아프리카 림프부종 치료 시장은 압박 요법 , 수술, 약물 요법, 레이저 요법 및 기타로 세분화됩니다. 2022년에는 수술에 비해 치료 비용이 낮기 때문에 압박 요법 부문이 시장을 지배할 것으로 예상됩니다.
- 중동 및 아프리카 림프부종 치료 시장은 유형에 따라 1차 림프부종과 2차 림프부종으로 세분화됩니다. 2022년에는 2차 림프부종 세그먼트가 질병에 대한 인식이 높아짐에 따라 시장을 지배할 것으로 예상됩니다.
- 영향을 받는 지역을 기준으로 중동 및 아프리카 림프부종 치료 시장은 생식기, 하지 및 상지로 세분화됩니다. 2022년에는 하지 세그먼트가 시장을 지배하여 림프부종의 유병률이 증가할 것으로 예상됩니다.
- 연령대를 기준으로 중동 및 아프리카 림프부종 치료 시장은 성인 및 노인으로 세분화됩니다. 2022년에는 약물 승인 증가로 인해 성인 세그먼트가 시장을 지배할 것으로 예상됩니다.
- 투여 경로를 기준으로 중동 및 아프리카 림프부종 치료 시장은 경구, 주사 및 기타로 세분화됩니다. 2022년에는 경구 세그먼트가 가장 효과적인 투여 방식이기 때문에 시장을 지배할 것으로 예상됩니다.
- On the basis of end user, Middle East and Africa lymphedema treatment market is segmented in hospitals, ambulatory surgical centres, speciality clinics and others. In 2022, hospitals segment is expected to dominate the market due to increasing patients opting for surgeries.
- On the basis of distribution channel, Middle East and Africa lymphedema treatment market is segmented in direct tender, pharmacy stores and others. In 2022, pharmacy stores segment is expected to dominate the market owing to the rising product launches by the key market players.
Middle East and Africa lymphedema Treatment Market Country Level Analysis
The Middle East and Africa lymphedema treatment market is analyzed and market size information is provided base, by treatment type, by type, by affected area, by age group, by route of administration, by end user, by distribution channel.
Countries covered in the Middle East and Africa lymphedema treatment market report are South Africa, Saudi Arabia, UAE, Egypt, Kuwait, Israel, and rest of Middle East and Africa.
South Africa is expected to dominate the Middle East and Africa lymphedema treatment market due to increasing rising government funding in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Rising healthcare expenditure and escalation in innovations and technologies in the Middle East and Africa lymphedema treatment market are creating new opportunities for players in the Middle East and Africa lymphedema treatment market
Middle East and Africa lymphedema treatment market region segment in the South Africa is expected to grow with the highest rate and it is dominating the region in the forecast period of 2022 to 2029 because of rising government funding.
Middle East and Africa lymphedema treatment market also provides you with detailed market analysis for every country growth in particular industry with the Middle East and Africa lymphedema treatment market sales, impact of advancement in Middle East and Africa lymphedema treatment market and changes in regulatory scenarios with their support for the Middle East and Africa lymphedema treatment market.
Competitive Landscape and Middle East and Africa Lymphedema Treatment Market Share Analysis
중동 및 아프리카 림프부종 치료 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭 및 호흡, 응용 프로그램 우세 및 기술 수명선 곡선입니다. 제공된 위의 데이터 포인트는 중동 및 아프리카 림프부종 치료 시장과 관련된 회사의 초점에만 관련이 있습니다.
보고서에서 다루는 주요 업체는 Bio Compression Systems, Inc., Lohmann & Rauscher, Mego Afek ltd, SIGVARIS, Tactile Systems Technology Inc., medi GmbH & Co. KG, Paul Hartmann AG, Sanyleg Srl, 3M, ConvaTec Inc., Julius Zorn GmbH, Cardinal Health, Inc., Smith & Nephew plc, ThermoTek, Huntleigh Healthcare Limited, Herantis Pharma Plc입니다. 이들은 중동 및 아프리카 림프부종 치료 시장 업체입니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 별도로 제공합니다.
또한 전 세계 여러 회사에서 다양한 제품 출시와 계약을 체결하면서 중동과 아프리카 림프부종 치료 시장이 더욱 활성화되고 있습니다.
예를 들어,
- 2021년 8월, AIROS Medical, Fist Assist Devices는 Fist Assist FA-1 압박 장치에 대한 독점적인 미국 유통 계약을 발표했습니다. 이 파트너십은 회사의 시장 성장을 촉진할 것입니다.
- 2018년 9월, SIGVARIS는 진행성 정맥 부종, 림프부종, 수술 후 부종 및 일반 부종을 관리하기 위한 점진적인 압박 및 봉쇄 특성을 갖춘 혁신적인 의류인 SECURE를 출시한다고 발표했습니다. 이 앱 출시는 사람들 사이에 인지도를 높여 시장 성장을 촉진했습니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL'S ANALYSIS
4.2 PORTER'S MODEL
5 PIPELINE ANALYSIS FOR MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET
6 EPIDEMIOLOGY
7 REGULATORY GUIDELINES FOR MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET
7.1 U.S.
7.2 EUROPE
7.3 INDIA
7.4 MEXICO
7.5 CANADA
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 RISE IN THE NUMBER OF LYMPHEDEMA CASES MIDDLE EAST & AFRICALY
8.1.2 INCREASE IN THE PREVALENCE OF CANCERS
8.1.3 INCREASING NUMBER OF HEALTHCARE FACILITIES
8.1.4 MULTIPLE THERAPIES
8.2 RESTRAINTS
8.2.1 HIGH COST OF TREATMENT
8.2.2 LACK OF AWARENESS ABOUT THE DISEASE
8.3 OPPORTUNITIES
8.3.1 DRUG APPROVALS
8.3.2 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS
8.4 CHALLENGES
8.4.1 NO PERMANENT CURE FOR LYMPHEDEMA
8.4.2 DIFFICULT REIMBURSEMENT
9 IMPACT OF COVID-19 ON THE MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET
9.1 IMPACT ON PRICE
9.2 IMPACT ON DEMAND
9.3 IMPACT ON SUPPLY CHAIN
9.4 STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS
9.5 CONCLUSION
10 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE
10.1 OVERVIEW
10.2 COMPRESSION THERAPY
10.2.1 BY PRODUCT
10.2.1.1 COMPRESSION PUMPS
10.2.1.2 COMPRESSION GARMENTS
10.2.1.2.1 COMPRESSION STOCKINGS
10.2.1.2.2 COMPRESSION SLEEVES
10.2.1.2.3 OTHERS
10.2.1.3 COMPRESSION BANDAGES & WRAPS
10.2.1.4 OTHERS
10.2.2 BY TECHNIQUE
10.2.2.1 STATIC COMPRESSION THERAPY
10.2.2.2 DYNAMIC COMPRESSION THERAPY
10.3 SURGERY
10.3.1 LYMPHOVENOUS TRANSPLANT
10.3.2 LYMPHATICOVENOUS ANASTOMOSIS
10.3.3 LIPOSUCTION
10.3.4 OTHERS
10.4 DRUG THERAPY
10.4.1 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
10.4.2 RETINOIDS
10.4.3 ANTIBIOTICS
10.4.4 OTHERS
10.5 LASER THERAPY
10.6 OTHERS
11 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET, BY TYPE
11.1 OVERVIEW
11.2 SECONDARY LYMPHEDEMA
11.3 PRIMARY LYMPHEDEMA
11.3.1 LYMPHEDEMA PRAECOX (MEIGE DISEASE)
11.3.2 CONGENITAL LYMPHEDEMA
11.3.3 LYMPHEDEMA TARDA
12 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA
12.1 OVERVIEW
12.2 LOWER EXTREMITY
12.3 UPPER EXTREMITY
12.4 GENITALIA
13 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP
13.1 OVERVIEW
13.2 ADULT
13.3 GERIATRIC
13.4 PEDIATRIC
14 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 ORAL
14.3 INJECTABLE
14.4 TOPICAL
15 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITAL
15.3 SPECIALTY CLINICS
15.4 AMBULATORY SURGICAL CENTERS
15.5 OTHERS
16 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 PHARMACY STORES
16.3 DIRECT TENDER
16.4 OTHERS
17 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET, BY REGION
17.1 MIDDLE EAST AND AFRICA
17.1.1 SOUTH AFRICA
17.1.2 SAUDI ARABIA
17.1.3 EGYPT
17.1.4 U.A.E
17.1.5 ISRAEL
17.1.6 KUWAIT
17.1.7 REST OF MIDDLE EAST AND AFRICA
18 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
19 SWOT ANALYIS
20 COMPANY PROFILE
20.1 TACTILE MEDICAL
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENT
20.1.6 CLINICAL TRIAL:
20.2 ESSITY (BSN MEDICAL GMBH)
20.2.1 COMPANY SNAPSHOT
20.2.2 COMPANY SHARE ANALYSIS
20.2.3 PRODUCT PORTFOLIO
20.2.4 RECENT DEVELOPMENT
20.3 3M
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENTS
20.3.6 NEW BUSINESS SEGMENT
20.3.7 ACQUISITION
20.4 CARDINAL HEALTH
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 COMPANY SHARE ANALYSIS
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENT
20.5 LOHMANN & RAUSCHER GMBH & CO. KG
20.5.1 COMPANY SNAPSHOT
20.5.2 COMPANY SHARE ANALYSIS
20.5.3 PRODUCT PORTFOLIO
20.5.4 RECENT DEVELOPMENT
20.6 AIROS MEDICAL, INC.
20.6.1 COMPANY SNAPSHOT
20.6.2 PRODUCT PORTFOLIO
20.6.3 RECENT DEVELOPMENT
20.6.4 PRODUCT LAUNCH:
20.7 AVET PHARMACEUTICALS INC.
20.7.1 COMPANY SNAPSHOT
20.7.2 PRODUCT PORTFOLIO
20.7.3 RECENT DEVELOPMENT
20.8 BIOCOMPRESSION SYSTEMS
20.8.1 COMPANY SNAPSHOT
20.8.2 PRODUCT PORTFOLIO
20.8.3 RECENT DEVELOPMENT
20.8.4 AGREEMENT
20.9 CONVATEC INC.
20.9.1 COMPANY SNAPSHOT
20.9.2 PRODUCT PORTFOLIO
20.9.3 RECENT DEVELOPMENT
20.1 HERANTIS PHARMA PLC
20.10.1 COMPANY SNAPSHOT
20.10.2 RECENT DEVELOPMENT
20.11 HUNTLEIGH HEALTHCARE LIMITED
20.11.1 COMPANY SNAPSHOT
20.11.2 PRODUCT PORTFOLIO
20.11.3 RECENT DEVELOPMENT
20.12 JUZO
20.12.1 COMPANY SNAPSHOT
20.12.2 PRODUCT PORTFOLIO
20.12.3 RECENT DEVELOPMENT
20.13 KOYA MEDICAL
20.13.1 COMPANY SNAPSHOT
20.13.2 PRODUCT PORTFOLIO
20.13.3 RECENT DEVELOPMENT
20.13.4 APPROVAL
20.14 MEDI GMBH & CO. KG
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENT
20.15 MEGO AFEK LTD
20.15.1 COMPANY SNAPSHOT
20.15.2 PRODUCT PORTFOLIO
20.15.3 RECENT DEVELOPMENT
20.15.4 APPLICATION LAUNCH:
20.16 PAUL HARTMANN AG
20.16.1 COMPANY SNAPSHOT
20.16.2 REVENUE ANALYSIS
20.16.3 PRODUCT PORTFOLIO
20.16.4 RECENT DEVELOPMENTS
20.17 SANYLEG SRL A SOCIO UNICO
20.17.1 COMPANY SNAPSHOT
20.17.2 PRODUCT PORTFOLIO
20.17.3 RECENT DEVELOPMENT
20.18 SIGVARIS GROUP
20.18.1 COMPANY SNAPSHOT
20.18.2 PRODUCT PORTFOLIO
20.18.3 RECENT DEVELOPMENTS
20.18.4 PRODUCT LAUNCHES:
20.19 SMITH +NEPHEW
20.19.1 COMPANY SNAPSHOT
20.19.2 REVENUE ANALYSIS
20.19.3 PRODUCT PORTFOLIO
20.19.4 RECENT DEVELOPMENT
20.2 THERMOTEK
20.20.1 COMPANY SNAPSHOT
20.20.2 PRODUCT PORTFOLIO
20.20.3 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
표 목록
TABLE 1 PIPELINE ANALYSIS FOR LYMPHEDEMA TREATMENT:
TABLE 2 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION 2020-2029 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA LASER THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA SECONDARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA LOWER EXTREMITY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA UPPER EXTREMITY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA GENITALIA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA ADULT IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA GERIATRIC IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA PEDIATRIC IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA ORAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA INJECTABLE IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA TOPICAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA HOSPITAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA SPECIALITY CLINICS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 35 MIDDLE EAST & AFRICA PHARMACY STORES IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 MIDDLE EAST & AFRICA DIRECT TENDER IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 MIDDLE EAST & AFRICA OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 52 SOUTH AFRICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 53 SOUTH AFRICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 54 SOUTH AFRICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 55 SOUTH AFRICA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 56 SOUTH AFRICA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 57 SOUTH AFRICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 58 SOUTH AFRICA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 59 SOUTH AFRICA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 60 SOUTH AFRICA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 61 SOUTH AFRICA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 62 SOUTH AFRICA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 63 SOUTH AFRICA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 64 SOUTH AFRICA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 65 SAUDI ARABIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 66 SAUDI ARABIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 67 SAUDI ARABIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 68 SAUDI ARABIA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 69 SAUDI ARABIA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 70 SAUDI ARABIA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 71 SAUDI ARABIA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 72 SAUDI ARABIA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 73 SAUDI ARABIA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 74 SAUDI ARABIA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 75 SAUDI ARABIA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 76 SAUDI ARABIA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 77 SAUDI ARABIA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 78 EGYPT LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 79 EGYPT COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 80 EGYPT COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 81 EGYPT COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 82 EGYPT SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 83 EGYPT DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 84 EGYPT LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 85 EGYPT PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 86 EGYPT LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 87 EGYPT LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 88 EGYPT LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 89 EGYPT LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 90 EGYPT LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 91 U.A.E LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 92 U.A.E COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 93 U.A.E COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 94 U.A.E COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 95 U.A.E LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 96 U.A.E DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 97 U.A.E LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 98 U.A.E PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 99 U.A.E LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 100 U.A.E LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 101 U.A.E LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 102 U.A.E LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 103 U.A.E LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 104 ISRAEL LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 105 ISRAEL COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 106 ISRAEL COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 107 ISRAEL COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 108 ISRAEL SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION))
TABLE 109 ISRAEL DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 110 ISRAEL LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 111 ISRAEL PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 112 ISRAEL LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 113 ISRAEL LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 114 ISRAEL LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 115 ISRAEL LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 116 ISRAEL LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 117 KUWAIT LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 118 KUWAIT COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 119 KUWAIT COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 120 KUWAIT COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 121 KUWAIT SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 122 KUWAIT DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 123 KUWAIT LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 124 KUWAIT PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 125 KUWAIT LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 126 KUWAIT LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 127 KUWAIT LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 128 KUWAIT LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 129 KUWAIT LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 130 REST OF MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
그림 목록
FIGURE 1 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET : SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET : DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET : DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET: MIDDLE EAST & AFRICA VS REGIONAL ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET : INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET : DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET : MARKET APPLICATION COVERAGE GRID
FIGURE 9 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET : VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET : SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF LYMPHEDEMA AND RISING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 TREATMENT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET AND ASIA-PACIFIC TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET
FIGURE 15 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, 2021
FIGURE 16 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, 2020-2029 (USD MILLION)
FIGURE 17 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2022-2029)
FIGURE 18 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 19 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET: BY TYPE, 2021
FIGURE 20 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET: BY TYPE, 2020-2029 (USD MILLION)
FIGURE 21 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 22 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, 2021
FIGURE 24 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, 2020-2029 (USD MILLION)
FIGURE 25 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, CAGR (2022-2029)
FIGURE 26 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, LIFELINE CURVE
FIGURE 27 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, 2021
FIGURE 28 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, 2020-2029 (USD MILLION)
FIGURE 29 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, CAGR (2022-2029)
FIGURE 30 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 31 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 32 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
FIGURE 33 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 34 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET: BY END USER, 2021
FIGURE 36 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 37 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET: BY END USER, CAGR (2022-2029)
FIGURE 38 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 40 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 41 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL ,CAGR (2022-2029)
FIGURE 42 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: SNAPSHOT (2021)
FIGURE 44 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY COUNTRY (2021)
FIGURE 45 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY COUNTRY (2022 & 2029)
FIGURE 46 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY COUNTRY (2021 & 2029)
FIGURE 47 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE (2022-2029)
FIGURE 48 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET: COMPANY SHARE 2021 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.